INBX - Company ID 0001739614
The table below shows Inhibrx, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $119.00K | $30.00K | $17.00K | $278.00K | $711.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $63.85M | $38.06M | $34.11M | $37.39M | $24.93M | $29.91M |
Inhibrx, Inc. reported annual revenue of $1.80M for fiscal year 2023. That is down 17.9% from $2.19M in fiscal 2022. Over the 5 fiscal years shown, annual revenue declined from $13.21M (FY 2019) to $1.80M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $9.97M |
| $7.89M |
| $7.26M |
| $6.40M |
| $5.35M |
| $5.40M |
| Operating income | -$73.83M | -$45.83M | -$41.34M | -$43.77M | -$30.00M | -$34.60M |
| Income tax | $0.00 | $2.00K | $5.00K | $0.00 | $0.00 | $4.00K |
| Net income | -$78.71M | -$51.79M | -$47.05M | -$48.92M | -$35.33M | -$37.73M |
| EPS (diluted) | -$1.44 | -$1.10 | -$1.08 | -$1.12 | -$0.90 | -$0.97 |